InsiderTrades.com logo
Claim Your Complimentary Bitcoin Reward
From Crypto Swap Profits   |   Ad
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Secure Your Spot Now
Frederic Chereau net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Frederic Chereau Biography and Net Worth

Insider of LogicBio Therapeutics
Fred Chereau has more than 25 years of experience guiding products from proof-of-concept and clinical trials through commercialization in biotechnology, pharmaceuticals, and medical devices. He has served as president and chief executive officer of LogicBio since 2016. Prior to joining LogicBio, Fred served as the president and chief operating officer of aTyr Pharma Inc. He also served as president and chief executive officer of Pervasis Therapeutics until its acquisition by Shire Pharmaceuticals where he had a critical impact on the development of the hereditary angioedema (HAE) franchise. Previously, Fred served in various roles at Genzyme including vice president and general manager of the Cardiovascular Business Unit, and held sales and marketing roles with a medical device company in France. He is also a member of the Board of Directors for Dynacure SAS. Fred holds a B.S. in physics from Paris University, a M.S. from ESC La Rochelle and an MBA from INSEAD.

What is Frederic Chereau's net worth?

The estimated net worth of Frederic Chereau is at least $541,000.71 as of April 16th, 2021. Mr. Chereau owns 261,353 shares of LogicBio Therapeutics stock worth more than $541,001 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Chereau may own. Additionally, Mr. Chereau receives a salary of $793,200.00 as Insider at LogicBio Therapeutics. Learn More about Frederic Chereau's net worth.

How old is Frederic Chereau?

Mr. Chereau is currently 55 years old. There are 5 older executives and no younger executives at LogicBio Therapeutics. Learn More on Frederic Chereau's age.

What is Frederic Chereau's salary?

As the Insider of LogicBio Therapeutics, Inc., Mr. Chereau earns $793,200.00 per year. Learn More on Frederic Chereau's salary.

How do I contact Frederic Chereau?

The corporate mailing address for Mr. Chereau and other LogicBio Therapeutics executives is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. LogicBio Therapeutics can also be reached via phone at (617) 245-0399 and via email at [email protected]. Learn More on Frederic Chereau's contact information.

Has Frederic Chereau been buying or selling shares of LogicBio Therapeutics?

Frederic Chereau has not been actively trading shares of LogicBio Therapeutics during the past quarter. Most recently, Frederic Chereau sold 7,542 shares of the business's stock in a transaction on Friday, April 16th. The shares were sold at an average price of $5.73, for a transaction totalling $43,215.66. Following the completion of the sale, the insider now directly owns 261,353 shares of the company's stock, valued at $1,497,552.69. Learn More on Frederic Chereau's trading history.

Who are LogicBio Therapeutics' active insiders?

LogicBio Therapeutics' insider roster includes Frederic Chereau (Insider), Kyle Chiang (COO), and Daniel Gruskin (Insider). Learn More on LogicBio Therapeutics' active insiders.

Frederic Chereau Insider Trading History at LogicBio Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2021Sell7,542$5.73$43,215.66261,353View SEC Filing Icon  
See Full Table

Frederic Chereau Buying and Selling Activity at LogicBio Therapeutics

This chart shows Frederic Chereau's buying and selling at LogicBio Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

LogicBio Therapeutics Company Overview

LogicBio Therapeutics logo
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $2.07
Low: $2.07
High: $2.07

50 Day Range

MA: $2.06
Low: $2.04
High: $2.07

2 Week Range

Now: $2.07
Low: $0.26
High: $3.77

Volume

N/A

Average Volume

652,526 shs

Market Capitalization

$68.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.61
Claim Your Complimentary Bitcoin Reward
From Crypto Swap Profits   |   Ad
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Secure Your Spot Now